Key result
In patients with hypertrophic cardiomyopathy, plasma adiponectin levels were significantly higher in those with left ventricular diastolic dysfunction (T(1/2) ≥ 35 ms).
Why the study?
Is plasma adiponectin associated with left ventricular diastolic dysfunction in patients with hypertrophic cardiomyopathy?
Observational (n=26)
Is plasma adiponectin associated with left ventricular diastolic dysfunction in patients with hypertrophic cardiomyopathy?
Plasma adiponectin levels correlate with LV pressure half-time, suggesting it may serve as a biomarker for left ventricular diastolic dysfunction in patients with hypertrophic cardiomyopathy.
Hypothesis-generating for adiponectin as LV diastolic dysfunction biomarker in HCM; prospective validation required before clinical consideration.
BACKGROUND: Adiponectin is an adipose-derived plasma protein that exhibits beneficial actions on the heart. Recently, it was shown that adiponectin levels were elevated in patients with systolic heart failure. OBJECTIVE: To investigate the association between adiponectin levels and left ventricular (LV) diastolic function in patients with hypertrophic cardiomyopathy (HCM), characterised by diastolic dysfunction. METHODS: Twenty-six patients with HCM showing LV ejection fraction of >60% were enrolled. LV pressure half-time (T(1/2)) was measured as an index of myocardial relaxation. Patients were divided into two groups on the basis of baseline T(1/2) (group A: T(1/2)< 35 ms, group B: T(1/2) > or = 35 ms). Blood samples were simultaneously collected from the coronary sinus (CS) and aortic root (Ao) as well as the peripheral vein (PV) for measurement of plasma adiponectin levels. RESULTS: Plasma adiponectin levels were significantly higher in group B than in group A. Adiponectin levels in the PV were positively correlated with the baseline T(1/2) in patients with HCM. The transcardiac gradient of adiponectin as calculated by the Ao-CS difference was significantly higher in group A than in group B. The transcardiac gradient of adiponectin also inversely correlated with the baseline T(1/2) and adiponectin levels in PV in patients with HCM. The expression of AdipoR1 but not AdipoR2 in the heart decreased in group B. The baseline T(1/2) was negatively associated with AdipoR1 expression in patients with HCM. CONCLUSIONS: These data document that adiponectin is an indicator of LV diastolic dysfunction in patients with HCM.
No takes yet. Share an insight, caveat, or question.
Shibata et al. (2009) conducted an observational in Hypertrophic cardiomyopathy (n=26). Left ventricular diastolic dysfunction (T(1/2) ≥ 35 ms) vs. T(1/2) < 35 ms was evaluated on Plasma adiponectin levels. In patients with hypertrophic cardiomyopathy, plasma adiponectin levels were significantly higher in those with left ventricular diastolic dysfunction (T(1/2) ≥ 35 ms).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: